What You Should Know
- Precision medicine has transitioned from “one-off” testing to organized institutional programs at more than three-quarters of surveyed U.S. health systems, according to new research from the Center for Connected Medicine (CCM) at UPMC.
- This represents a massive shift from 2020, when 69% of organizations had little to no precision medicine deployment.
- While adoption is high, reimbursement uncertainty, high costs, and operational complexity remain the primary barriers to wider clinical use.
- Artificial Intelligence (AI) and advanced analytics are now critical drivers for scaling, specifically in clinical decision support and diagnostics.
- Clinical progress is most visible in oncology, pharmacogenomics, and maternal-fetal health, where evidence and actionability are strongest.
Precision medicine—the practice of tailoring medical treatment to the individual characteristics of each patient—has officially moved from the fringes of research into the mainstream of clinical operations. According to a 2026 report by the Center for Connected Medicine (CCM) at UPMC, conducted with KLAS Research, the industry is undergoing a “true evolution”. What was once a collection of isolated tests is now being organized into formal institutes and dedicated service lines across the majority of midsize and large U.S. health systems.
However, the “last mile” of implementation remains the most difficult. While the technology to sequence a genome has matured, the practical work of embedding those results into everyday electronic health record (EHR) workflows is still a work in progress. For precision medicine to become “standard” rather than just “available,” health systems must overcome a complex web of financial and operational hurdles that currently prevent universal patient access.
The Shift from Discovery to Operations
The data indicates a rapid maturation of the field over the last five years. In 2020, nearly 70% of health systems were still in the nascent stages of precision medicine. By early 2026, that dynamic has flipped, with 76% of surveyed organizations reporting formal programs. This growth is fueled by a deeper integration of genetic data into clinical decision support tools, which help physicians understand exactly how to act on a genetic result at the point of care.
Leaders in the field, such as Adrian Lee, Ph.D., of the Institute for Precision Medicine, emphasize that the current phase is focused on accessibility. To reach all patients, organizations are prioritizing areas with clear “clinical actionability”. This includes pharmacogenomics—using a patient’s DNA to determine the safest and most effective drug dosage—as well as oncology and maternal-fetal health, where genetic insights have the most immediate impact on treatment paths.
Overcoming the Barriers: AI and Collaboration
Despite the excitement surrounding new diagnostic capabilities, three recurring barriers threaten to stall progress: cost, lack of reimbursement, and workflow complexity. Health systems often struggle to justify the expense of large-scale genetic testing when insurance coverage remains inconsistent, particularly for preventive or population-based screenings. Matthias Kleinz, Ph.D., of UPMC Enterprises, argues that overcoming these hurdles will require a new era of “cross-functional” collaboration between institutions and payers to build a stronger evidence base for the value of these tests.
A major differentiator in the 2026 findings compared to the 2020 baseline is the pervasive role of Artificial Intelligence. AI is now being utilized to automate the labor-intensive “matching” of genetic variants to clinical treatments, a process that was largely manual just a few years ago. By using advanced analytics to surface relevant insights directly within the EHR, health systems are finding ways to scale precision medicine beyond elite specialty clinics and into the hands of primary care providers.
Why This Matters
The fact that 76% of systems have formal programs means the debate over if precision medicine is valuable is over; the new debate is over who pays and how it fits into a busy nurse’s or doctor’s afternoon. The organizations that win this decade will be those that use AI to make genetic data “invisible” but actionable within the EHR, and those that can successfully negotiate with payers to recognize genetic testing as a cost-saving preventive tool rather than an expensive experimental line item.
